Early Life and Education
Michelle Xia was born in Gansu province, China, to university-educated engineers. She received a Bachelor's degree in biochemistry from Sun Yat-sen University in Guangzhou in 1988. She furthered her education by obtaining a Ph.D. in molecular biology and microbiology from Newcastle University in the U.K. in 1994. Xia also completed postdoctoral research at the University of Glasgow and conducted cancer immune therapy research at the University of Louisville School of Medicine in the U.S.
Rise to Success
Michelle Xia has over 26 years of experience in the pharmaceutical industry and academic research. Prior to founding Akeso Biopharma in 2012, Xia held senior leadership roles at Crown Bioscience Inc., where she played a key role in constructing the company's platform. She also worked as a senior scientist and group leader at PDL BioPharma, Inc. (later acquired by Abbvie). Xia's pharmaceutical career began at Axys Pharmaceuticals, Inc. (later acquired by Celera Genomics), where she held scientific and managerial roles.
Key Business Strategies
Xia founded Akeso Biopharma with a vision to make therapeutic antibody drugs accessible and affordable. The company focused on research and development, manufacturing, and commercialization of innovative antibody drugs. One of Akeso's key achievements is the development of ivonescimab, which outperformed Merck's Keytruda in a Phase 3 trial for lung cancer. Akeso has also licensed its drug candidate to Summit Therapeutics, which has expanded Xia's reach in the market.
Philanthropy
Information on specific philanthropy amounts for Michelle Xia was not found in the search results.
